Tim-3, a negative regulator of anti-tumor immunity
- PMID: 22226204
- DOI: 10.1016/j.coi.2011.12.005
Tim-3, a negative regulator of anti-tumor immunity
Abstract
T cell immunoglobulin-3 (Tim-3) was identified nearly 10 years ago as a negative regulator of IFN-γ-secreting CD4(+) T helper 1 and CD8(+) T cytotoxic 1 cells. Tim-3 is now classed with other inhibitory receptors, such as cytotoxic lymphocyte antigen-4 and programmed death-1 that are commonly referred to as immune checkpoint molecules. Recent studies have highlighted Tim-3 as an important player in the CD8(+) T cell exhaustion that takes place in chronic immune conditions such as chronic viral infection and cancer in both humans and experimental models. In addition to its role in exhausted T cells, recent data suggest that Tim-3 can further influence cancer outcome through its action on myeloid cells and cancer stem cells.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
[Regulation of T-cell immune exhaustion and cancer immunotherapy].Gan To Kagaku Ryoho. 2014 Sep;41(9):1066-70. Gan To Kagaku Ryoho. 2014. PMID: 25248889 Japanese.
-
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.Nature. 2015 Jan 15;517(7534):386-90. doi: 10.1038/nature13848. Epub 2014 Oct 26. Nature. 2015. PMID: 25363763 Free PMC article.
-
TIM-3 and its regulatory role in immune responses.Curr Top Microbiol Immunol. 2011;350:1-15. doi: 10.1007/82_2010_84. Curr Top Microbiol Immunol. 2011. PMID: 20700701 Review.
-
Multiple roles for CD4+ T cells in anti-tumor immune responses.Immunol Rev. 2008 Apr;222:129-44. doi: 10.1111/j.1600-065X.2008.00616.x. Immunol Rev. 2008. PMID: 18363998 Review.
-
[Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].Bull Cancer. 2003 Aug-Sep;90(8-9):677-85. Bull Cancer. 2003. PMID: 14609756 Review. French.
Cited by
-
Abnormal expression of Tim-3 antigen on peripheral blood T cells is associated with progressive disease in osteosarcoma patients.FEBS Open Bio. 2016 Jul 9;6(8):807-15. doi: 10.1002/2211-5463.12079. eCollection 2016 Aug. FEBS Open Bio. 2016. PMID: 27516959 Free PMC article.
-
Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.Front Immunol. 2013 Dec 3;4:417. doi: 10.3389/fimmu.2013.00417. Front Immunol. 2013. PMID: 24348481 Free PMC article. Review.
-
Stimulation of Camel Polyclonal Antibody against Human T cell Immunoglobulin and Mucin 3.Iran J Biotechnol. 2017 Sep 27;15(3):166-171. doi: 10.15171/ijb.1427. eCollection 2017. Iran J Biotechnol. 2017. PMID: 29845065 Free PMC article.
-
RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression.Stem Cells Transl Med. 2014 Jul;3(7):836-48. doi: 10.5966/sctm.2013-0193. Epub 2014 May 22. Stem Cells Transl Med. 2014. PMID: 24855276 Free PMC article.
-
Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.Oncotarget. 2017 Jun 20;8(25):41641-41669. doi: 10.18632/oncotarget.16335. Oncotarget. 2017. PMID: 28404974 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials